MBT-C101 is a selective, potentially first-in-class potent HSP90 chaperone-mediated degrader of PI3Kα, for the treatment of breast cancer. It was developed by Magicbullet Therapeutics Inc. using the company’s Chaperone-mediated Degrader (CM-Degrader) platform.
The transcription factor IKZF2 is a marker of highly suppressive regulatory T cells (Tregs). When IKZF2 is degraded, Tregs become effector-like T cells leading to increased antitumor immune response in the tumor microenvironment.
Trogenix Ltd. has emerged from stealth with a focus on treating cancer through viral immunotherapy. The company was founded as a spinout from the University of Edinburgh last year.
Cancer Targeted Technology LLC has been awarded the phase I portion ($400,000) of a fast track phase I/II ($2.4 million) Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop CTT-2274 to treat metastatic prostate cancer.
Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as cancer immunotherapy.
Previous studies reported that cellular communication network factor 1 (CCN1) is overexpressed in the endothelial cells and synovial tissue of patients with rheumatoid arthritis (RA). French researchers have now investigated the effects of inhibiting CCN1 in two murine models of RA with the aim of proposing CCN1 as a potential therapeutic target in RA.
Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to license the therapy for further development and commercialization, resulting in a milestone payment to Quell of $10 million.
Researchers from Exelixis Inc. described the preclinical characterization of XB-002, an antibody-drug conjugate consisting of a monoclonal antibody recognizing a tissue factor (TF) epitope that does not interfere with factor VII binding.
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug discovery purposes, among other uses. Now, scientists at the Arc Institute have created Evo, an AI model that generates DNA sequences and estimates their interaction with other molecules at single-nucleotide resolution, scalable to an entire genome.
While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of research excluding women from clinical trials and investment decisions.
RSS
